Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

Rheumatoid Arthritis

Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials

Semin Arthritis Rheum

Pugliesi A, Oliveira DGC, Filho VAS, Machado JO, Pereira AG, Bichuette JCS, Sachetto Z, de Carvalho LSF, Bertolo MB

doi: 10.1016/j.semarthrit.2024.152563

Systemic Lupus Erythematosus

Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation

Arthritis Rheumatol

Ma KS, Lo JE, Kyttaris VC, Tsokos GC, Costenbader KH

doi: 10.1002/art.43037

Psoriatic ArthritisRheumatoid Arthritis

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Ann Rheum Dis

Hernández-Cruz B, Otero-Varela L, Freire-González M, Busquets-Pérez N, García González AJ, Moreno-Ramos M, Blanco-Madrigal JM, Manrique-Arija S, Perez-Pampin E, Ruiz-Montesino D, Sánchez-Alonso F, Sanchez-Piedra C, Castrejón I, BIOBADASER Study Group

doi: 10.1136/ard-2023-225271

Rheumatoid Arthritis

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

Ann Rheum Dis

Burmester GR, Gottenberg JE, Caporali R, Winthrop KL, Tanaka Y, Ekoka Omoruyi EV, Rajendran V, Van Hoek P, Van Beneden K, Takeuchi T, Westhovens R, Aletaha D

doi: 10.1136/ard-2024-225759

Rheumatoid Arthritis

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Ann Rheum Dis

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A

doi: 10.1136/ard-2024-226286

Psoriatic Arthritis

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Ther Adv Musculoskelet Dis

Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA

doi: 10.1177/1759720X241288071

Rheumatoid Arthritis

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Rheumatol Ther

Taylor PC, Fakhouri W, Ogwu S, Haladyj E, de la Torre I, Fautrel B, Alten R, Nash P, Feist E

doi: 10.1007/s40744-024-00732-8

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Rheumatoid Arthritis

Efficacy and safety of abatacept in preclinical rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials

Semin Arthritis Rheum

Asif M, Asif A, Rahman UA, Haseeb A, Jafar U, Farooq H

doi: 10.1016/j.semarthrit.2024.152562

Related content

Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials

Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies

Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Efficacy and safety of abatacept in preclinical rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials